Compare PEBK & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PEBK | SABS |
|---|---|---|
| Founded | 1912 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.0M | 181.4M |
| IPO Year | N/A | N/A |
| Metric | PEBK | SABS |
|---|---|---|
| Price | $36.10 | $3.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $10.50 |
| AVG Volume (30 Days) | 11.2K | ★ 299.4K |
| Earning Date | 02-11-2026 | 11-13-2025 |
| Dividend Yield | ★ 2.65% | N/A |
| EPS Growth | ★ 3.81 | N/A |
| EPS | ★ 3.06 | N/A |
| Revenue | ★ $85,500,000.00 | $114,698.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.83 | ★ N/A |
| Revenue Growth | ★ 6.88 | N/A |
| 52 Week Low | $23.74 | $1.00 |
| 52 Week High | $38.46 | $6.60 |
| Indicator | PEBK | SABS |
|---|---|---|
| Relative Strength Index (RSI) | 57.46 | 49.71 |
| Support Level | $36.15 | $3.48 |
| Resistance Level | $38.40 | $4.00 |
| Average True Range (ATR) | 0.79 | 0.19 |
| MACD | -0.32 | -0.04 |
| Stochastic Oscillator | 10.61 | 42.96 |
Peoples Bancorp of North Carolina Inc is a bank holding company. It is a state-chartered commercial bank serving Lincolnton, Newton, Denver, Catawba, Conover, Maiden, Claremont, Hiddenite, Hickory, Charlotte, Cornelius, Raleigh and Cary, North Carolina. It has a diversified loan portfolio with no foreign loans and few agricultural loans. The company's main source of income is dividends declared and paid by the Bank on its capital stock.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.